Simpson Interventions Receives FDA Breakthrough Device Designation for Acolyte™ Image Guided Crossing and Re-Entry Catheter System

Summation

  • The Acolyte Image Guided Crossing and Re-Entry Catheter System is designed to facilitate the placement and positioning of guidewires and catheters within the coronary vasculature for the treatment of patients with coronary chronic total occlusions (CTOs) who continue to experience symptoms following medical therapy.
  • Simpson Interventions is committed to collaborating closely with the FDA and other stakeholders to advance the development and regulatory review of the Acolyte Image Guided Crossing and Re-Entry Catheter System.
  • , a pioneering medical technology company specializing in cardiovascular interventional devices, today announced that its groundbreaking Acolyte Image Guided Crossing and Re-Entry Catheter System has been granted Breakthrough Device Designation by the U.

Simpson Interventions, Inc., a pioneering medical technology company specializing in cardiovascular interventional devices, today announced that its groundbreaking Acolyte Image Guided Crossing and Re-Entry Catheter System has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).

Acolyte Image Guided Crossing and Re-Entry Catheter System

The Acolyte Image Guided Crossing and Re-Entry Catheter System is designed to facilitate the placement and positioning of guidewires and catheters within the coronary vasculature for the treatment of patients with coronary chronic total occlusions (CTOs) who continue to experience symptoms following medical therapy. This breakthrough device is poised to significantly change the approach to treating coronary CTOs by providing real-time optical coherence tomography (OCT) visualization, enabling precise guidewire placement within the target vessel’s true lumen and subsequent revascularization.

Journal of the American College of Cardiology

According to the Journal of the American College of Cardiology: Cardiovascular Interventions, sixteen to twenty percent of patients with coronary artery disease have CTOs[1], which occur when a coronary artery is completely blocked by plaque buildup, posing significant challenges for interventional cardiologists who struggle to traverse these lesions with current standard of care options. If a physician fails to cross a CTO, minimally invasive revascularization options such as angioplasty and stent placement cannot be performed. Hence, in the US, many CTO patients are instead sent for bypass surgery. The Acolyte Image Guided Crossing and Re-Entry Catheter System aims to overcome these challenges by providing clinicians with this breakthrough device that has enhanced visualization and navigation capabilities, ultimately improving CTO crossing, procedural success rates, and patient outcomes.

Dr. John B. Simpson, PhD, MD, Founder and CEO of Simpson Interventions

“We are thrilled to receive FDA’s Breakthrough Device Designation for our Acolyte Image Guided Crossing and Re-Entry Catheter System. This designation recognizes the transformative potential of our technology in addressing a critical unmet need in the treatment of patients with coronary chronic total occlusions. We are committed to advancing the field of interventional cardiology and improving patient outcomes through innovation.”

Potential Advantages

The FDA’s Breakthrough Device Designation is granted to medical devices that offer potential advantages over existing technologies for the treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. This designation expedites the development, assessment, and review process, enabling patients to gain access to innovative medical technologies more quickly.

Simpson Interventions is committed to collaborating closely with the FDA and other stakeholders to advance the development and regulatory review of the Acolyte Image Guided Crossing and Re-Entry Catheter System. The company looks forward to bringing this revolutionary technology to clinicians, and patients in need.

[1] https://www.jacc.org/doi/10.1016/j.jcin.2021.09.027

Other FDA News of Interest

Indica Labs Receives FDA Clearance for HALO AP Dx Digital Pathology Platform for Use with Hamamatsu Images Acquired with the NanoZoomer® S360MD Slide Scanner

Indica Labs, an industry leader in AI-powered digital pathology solutions, and Hamamatsu Photonics K.K., a pioneer in whole slide imaging systems, announce that the...

FDA Grants AI-Powered Notal Vision Home OCT “SCANLY” De Novo Marketing Authorization

“We are very excited to receive FDA authorization to market SCANLY Home OCT as the first-ever patient self-operated, home-use device that gives physicians remote access to high-resolution, cross-sectional retinal images and AI-based analytical biomarkers of their patients eyes between office visits,” said Kester Nahen, PhD, CEO of Notal Vision. “We look forward to supporting our referring physicians in navigating their wet AMD patients’ care.”

Atraverse Medical Receives FDA Clearance for HOTWIRE™ Left Heart Access Device, Oversubscribes Seed Round with $12.5M Invested

The HOTWIRE system, invented by Atraverse Medical Co-Founders Dr. Steven Mickelsen and Eric Sauter, introduces a paradigm shift in left-heart access.

By using this website you agree to accept Medical Device News Magazine Privacy Policy